간편하게 보는 뉴스는 유니콘뉴스
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

· 등록일 Aug. 13, 2024 16:19

· 업데이트일 2024-08-14 00:00:20

ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.1 Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA - a status reserved for medicines with the potential to significantly improve the treatment of serious conditions.

Prurigo nodularis is an underdiagnosed neuroimmune skin disease which is estimated to affect up to 181,000 people in the United States.[7,8] This condition is characterized by several debilitating symptoms, including chronic itch, skin nodules covering large body areas, and poor sleep quality.[5,9] Given the significant burden on patients, there is a need for alternative treatment options that may effectively relieve key signs and symptoms of the disease.[10] Nemluvio specifically inhibits IL-31 cytokine signaling, which is known to drive itch and is involved in inflammation, altered epidermal differentiation, and fibrosis (hardening of skin tissue) in prurigo nodularis.[1-3,11,12]

“The U.S. FDA’s rapid approval of Nemluvio in prurigo nodularis is a first step in achieving its blockbuster platform potential and reinforces our leadership in therapeutic dermatology. We’re confident in the impact this first-in-class therapy will have for patients with prurigo nodularis who urgently need more treatment options and look forward to potentially bringing Nemluvio to patients with other itch-related skin diseases in the near future.”

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

The approval is based on positive results from the phase III OLYMPIA clinical trials - the largest clinical trial program conducted in this condition to date - in which Nemluvio demonstrated significant and clinically meaningful improvements in itch and skin nodules at Week 16, with rapid reductions in itch observed as early as Week [4.1,13-16]

The phase III OLYMPIA 1 and OLYMPIA 2 clinical trials evaluated the efficacy and safety of Nemluvio administered subcutaneously every four weeks in more than 500 patients with prurigo nodularis.[13-16] The trials met both their primary and key secondary endpoints, demonstrating that:

·56% and 49% of Nemluvio-treated patients in OLYMPIA 1 and 2 respectively, achieved at least a four-point reduction in itch intensity at Week 16, as measured by the peak-pruritus numerical rating scale, compared to 16% in both placebo groups (p
배포 분야
인기 기사12.24 11시 기준
저지시티, 뉴저지--(Business Wire / 뉴스와이어)--여성 건강에 중점을 둔 글로벌 헬스케어 기업인 오가논(Organon)(NYSE:OGN)이 일라이 릴리 앤 컴퍼니(릴리)(Eli Lilly and Company, Lilly)와 유럽에서 편두통 치료제 엠갈리티®(Emgality®)(갈카네주맙)와 레이보우™(RAYVOW™)(라스미디탄)의 단독 유통업체 및 프로모터가 되는 계약을 체결했다고 발표했다.[1] 인간화...
샌 마테오, 캘리포니아--(뉴스와이어)--24일 저녁(영국 현지시간) 맨체스터 유나이티드(Manchester United, 이하 맨유)의 24/25 시즌 공식 어웨이 유니폼이 출시에 앞서 글로벌 메타버스 플랫폼 로블록스에서 최초 공개됐다. 맨유가 24/25...
SEOUL--(Korea Newswire)--The 11th Mullae Metal City (MMC) Festival will take place on July 20-21, 2024, at the ‘Yeongdeungpo Art Hall’(596, Gukhoe-daero, Yeongdeungpo-gu) in Seoul. The festival will feature performances by top Korean heavy metal...
서울--(뉴스와이어)--사이버한국외국어대학교(총장 장지호) 마케팅·경영학부 김병철 교수가 2024년 제43회 스승의 날을 맞아 교육 발전에 공헌한 교원에게 수여하는 사회부총리 겸 교육부장관 표창을 받았다. 사이버한국외대 마케팅·경영학부 김병철 교수가 제43회...
서울--(뉴스와이어)--드라마 및 버추얼 휴먼 콘텐츠 제작사 스튜디오메타케이(대표 김광집)가 문화체육관광부가 주최하고 한국콘텐츠진흥원이 주관하는 ‘더 어울림(Oulim) in 도쿄’에서 버추얼 아티스트 ‘그린’의 콘텐츠를 전시한다. ‘더 어울림(Oulim) in 도쿄’...
서울--(뉴스와이어)--도레이첨단소재(대표이사 사장 전해상)가 올해로 60주년을 맞는 무역의 날을 맞아 2023년 ‘8억불 수출의 탑’을 수상했다. 전해상 도레이첨단소재 대표이사 사장 도레이첨단소재는 폴리에스터 필름 및 IT소재, 탄소섬유 복합재료, PPS수지, 수처리 필터, 스펀본드 부직포, 원면, 원사, 아라미드 등 각...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.